Intranasal Oxytocin in Pediatric Populations: Exploring the Potential for Reducing Irritability and Modulating Neural Responses: A Mini Review-Journal of Psychiatry and Brain Science-CSCIED科技核心评价数据库-手机版

Intranasal Oxytocin in Pediatric Populations: Exploring the Potential for Reducing Irritability and Modulating Neural Responses: A Mini Review

Intranasal Oxytocin in Pediatric Populations: Exploring the Potential for Reducing Irritability and Modulating Neural Responses: A Mini Review

ES评分 0 浏览量：481 下载量：0

全文阅读下载引用收藏

DOI	10.20900/jpbs.20230008
刊名	Journal of Psychiatry and Brain Science JPBS
年，卷(期)	2023, 8(4)
作者	Kennet Sorenson,Emilee Kendall,Hannah Grell,Minjoo Kang,Christopher Shaffer,Soonjo Hwang*,
作者单位	1 Department of Psychiatry, University of Nebraska Medical Center, Omaha, NE 68198, USA; 2 Department of Pharmacy Practice, University of Nebraska Medical Center, Omaha, NE 68198, USA
Abstract	Endogenous neuropeptide Oxytocin (OXT) plays a crucial role in modulating pro-social behavior and the neural response to social/emotional stimuli. Intranasal administration is the most common method of delivering OXT. Intranasal OXT has been implemented in clinical studies of various psychiatric disorders with mixed results, mainly related to lack of solid pharmacodynamics and pharmacokinetics model. Due to intranasal OXT’s mechanism of reducing the activation of neural areas implicated in emotional responding and emotion regulation, a psychopathology with this target mechanism could be potentially excellent candidate for future clinical trial. In this regard, irritability in youth may be a very promising target for clinical studies of intranasal OXT. Here we provide a mini-review of fifteen randomized controlled trials in pediatric patients with diagnoses of autism spectrum disorder (ASD), Prader-Willi syndrome (PWS), or Phelan-McDermid syndrome (PMS). Most studies had small sample sizes and varying dosages, with changes in irritability, mainly as adverse events (AEs). Neuroimaging results showed modulation of the reward processing system and the neural areas implicated in social-emotional information processing by intranasal OXT administration. Further research is needed to determine the most effective dose and duration of OXT treatment, carefully select target psychopathologies, verify target engagement, and measure adverse event profiles.
KeyWord	intranasal oxytocin; OXT pediatric; autism spectrum disorder (ASD); Prader-Willi (PWS); Phelan-McDermid (PMS); irritability
基金项目
页码	-

参考文献
相关文献

1. Gordon I, Jack A, Pretzsch C, Vander Wyk B, Leckman JF, Feldman R, et al. Intranasal Oxytocin Enhances Connectivity in the Neural Circuitry Supporting Social Motivation and Social Perception in Children with Autism. Sci Rep. 2016 Nov 15;6:35054. doi: 10.1038/srep35054 2. Froemke RC, Young LJ. Oxytocin, Neural Plasticity, and Social Behavior. Annu Rev Neurosci. 2021 Jul 8;44:359-81. doi: 10.1146/annurev-neuro-102320-102847 3. Adolphs R. The social brain: neural basis of social knowledge. Annu Rev Psychol. 2009;60:693-716. doi: 10.1146/annurev.psych.60.110707.163514 4. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001 Apr;81(2):629-83. doi: 10.1152/physrev.2001.81.2.629 5. 5.Veening JG, Olivier B. Intranasal administration of oxytocin: behavioral and clinical effects, a review. Neurosci Biobehav Rev. 2013 Sep;37(8):1445-65. doi: 10.1016/j.neubiorev.2013.04.012 6. Kirsch P, Esslinger C, Chen Q, Mier D, Lis S, Siddhanti S, et al. Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci. 2005 Dec 7;25(49):11489-93. doi: 10.1523/JNEUROSCI.3984-05.2005 7. 7.Grace SA, Rossell SL, Heinrichs M, Kordsachia C, Labuschagne I. Oxytocin and brain activity in humans: A systematic review and coordinate-based meta-analysis of functional MRI studies. Psychoneuroendocrinology. 2018 Oct;96:6-24. doi: 10.1016/j.psyneuen.2018.05.031 8. Gordon I, Vander Wyk BC, Bennett RH, Cordeaux C, Lucas MV, Eilbott JA, et al-. Oxytocin enhances brain function in children with autism. Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):20953-8. doi: 10.1073/pnas.1312857110 9. Domes G, Heinrichs M, Kumbier E, Grossmann A, Hauenstein K, Herpertz SC. Effects of intranasal oxytocin on the neural basis of face processing in autism spectrum disorder. Biol Psychiatry. 2013 Aug 1;74(3):164-71. doi: 10.1016/j.biopsych.2013.02.007 10. Gamer M, Zurowski B, Büchel C. Different amygdala subregions mediate valence-related and attentional effects of oxytocin in humans. Proc Natl Acad Sci U S A. 2010 May 18;107(20):9400-5. doi: 10.1073/pnas.1000985107 11. Watanabe T, Kuroda M, Kuwabara H, Aoki Y, Iwashiro N, Tatsunobu N, et al. Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism. Brain. 2015 Nov;138(Pt 11):3400-12. doi: 10.1093/brain/awv249 12. Kendrick KM, Guastella AJ, Becker B. Overview of Human Oxytocin Research. Curr Top Behav Neurosci. 2018;35:321-348. doi: 10.1007/7854_2017_19 13. Oxytocin. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Oxytocin. Accessed 2023 August 31. 14. Dopamine. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Dopamine. Accessed 2023 August 31. 15. Buijs RM. Intra- and extrahypothalamic vasopressin and oxytocin pathways in the rat. Pathways to the limbic system, medulla oblongata and spinal cord. Cell Tissue Res. 1978 Sep 26;192(3):423-35. doi: 10.1007/BF00212323 16. Descamps D, Evnouchidou I, Caillens V, Drajac C, Riffault S, van Endert P, et al. The Role of Insulin Regulated Aminopeptidase in Endocytic Trafficking and Receptor Signaling in Immune Cells. Front Mol Biosci. 2020 Oct 20;7:583556. doi: 10.3389/fmolb.2020.583556 17. Georgiadis D, Ziotopoulou A, Kaloumenou E, Lelis A, Papasava A. The Discovery of Insulin-Regulated Aminopeptidase (IRAP) Inhibitors: A Literature Review. Front Pharmacol. 2020 Sep 23;11:585838. doi: 10.3389/fphar.2020.585838 18. Gossen A, Hahn A, Westphal L, Prinz S, Schultz RT, Gründer G, et al. Oxytocin plasma concentrations after single intranasal oxytocin administration—a study in healthy men. Neuropeptides. 2012 Oct;46(5):211-5. doi: 10.1016/j.npep.2012.07.001 19. Feifel D, Shilling PD, MacDonald K. A Review of Oxytocin's Effects on the Positive, Negative, and Cognitive Domains of Schizophrenia. Biol Psychiatry. 2016 Feb 1;79(3):222-33. doi: 10.1016/j.biopsych.2015.07.025 20. Herpertz S, Nizielski S, Hock M, Schütz A. The Relevance of Emotional Intelligence in Personnel Selection for High Emotional Labor Jobs. PLoS One. 2016 Apr 28;11(4):e0154432. doi: 10.1371/journal.pone.0154432 21. Domes G, Ower N, von Dawans B, Spengler FB, Dziobek I, Bohus M, et al. Effects of intranasal oxytocin administration on empathy and approach motivation in women with borderline personality disorder: a randomized controlled trial. Transl Psychiatry. 2019 Dec 4;9(1):328. doi: 10.1038/s41398-019-0658-4 22. Munesue T, Nakamura H, Kikuchi M, Miura Y, Takeuchi N, Anme T, et al. Oxytocin for Male Subjects with Autism Spectrum Disorder and Comorbid Intellectual Disabilities: A Randomized Pilot Study. Front Psychiatry. 2016 Jan 21;7:2. doi: 10.3389/fpsyt.2016.00002 23. Scantamburlo G, Hansenne M, Geenen V, Legros JJ, Ansseau M. Additional intranasal oxytocin to escitalopram improves depressive symptoms in resistant depression: an open trial. Eur Psychiatry. 2015 Jan;30(1):65-8. doi: 10.1016/j.eurpsy.2014.08.007 24. Corbett BA, Bales KL, Swain D, Sanders K, Weinstein TA, Muglia LJ. Comparing oxytocin and cortisol regulation in a double-blind, placebo-controlled, hydrocortisone challenge pilot study in children with autism and typical development. J Neurodev Disord. 2016 Aug 18;8:32. doi: 10.1186/s11689-016-9165-6 25. Dadds MR, MacDonald E, Cauchi A, Williams K, Levy F, Brennan J. Nasal oxytocin for social deficits in childhood autism: a randomized controlled trial. J Autism Dev Disord. 2014 Mar;44(3):521-31. doi: 10.1007/s10803-013-1899-3 26. Sikich L, Kolevzon A, King BH, McDougle CJ, Sanders KB, Kim SJ, et al. Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder. N Engl J Med. 2021 Oct 14;385(16):1462-73. doi: 10.1056/NEJMoa2103583 27. Bigler ED, Mortensen S, Neeley ES, Ozonoff S, Krasny L, Johnson M, et al. Superior temporal gyrus, language function, and autism. Dev Neuropsychol. 2007;31(2):217-38. doi: 10.1080/87565640701190841 28. Oiesvold T, Nivison M, Hansen V, Skre I, Ostensen L, Sørgaard KW. Diagnosing comorbidity in psychiatric hospital: challenging the validity of administrative registers. BMC Psychiatry. 2013 Jan 8;13:13. doi: 10.1186/1471-244X-13-13 29. Dell'osso L, Pini S. What Did We Learn from Research on Comorbidity In Psychiatry? Advantages and Limitations in the Forthcoming DSM-V Era. Clin Pract Epidemiol Ment Health. 2012;8:180-4. doi: 10.2174/1745017901208010180 30. Banerjee A, Chitnis UB, Jadhav SL, Bhawalkar JS, Chaudhury S. Hypothesis testing, type I and type II errors. Ind Psychiatry J. 2009 Jul;18(2):127-31. doi: 10.4103/0972-6748.62274 31. Leng G, Ludwig M. Intranasal Oxytocin: Myths and Delusions. Biol Psychiatry. 2016 Feb 1;79(3):243-50. doi: 10.1016/j.biopsych.2015.05.003 32. Leibenluft E. Pediatric Irritability: A Systems Neuroscience Approach. Trends Cogn Sci. 2017 Apr;21(4):277-89. doi: 10.1016/j.tics.2017.02.002 33. Leibenluft E, Kircanski K. Chronic Irritability in Youth: A Reprise on Challenges and Opportunities Toward Meeting Unmet Clinical Needs. Child Adolesc Psychiatr Clin N Am. 2021 Jul;30(3):667-83. doi: 10.1016/j.chc.2021.04.014 34. Leibenluft E, Stoddard J. The developmental psychopathology of irritability. Dev Psychopathol. 2013 Nov;25(4 Pt 2):1473-87. doi: 10.1017/S0954579413000722 35. Kempes M, Matthys W, de Vries H, van Engeland H. Reactive and proactive aggression in children--a review of theory, findings and the relevance for child and adolescent psychiatry. Eur Child Adolesc Psychiatry. 2005 Feb;14(1):11-9. doi: 10.1007/s00787-005-0432-4 36. Radke S, Volman I, Kokal I, Roelofs K, de Bruijn ERA, Toni I. Oxytocin reduces amygdala responses during threat approach. Psychoneuroendocrinology. 2017 May;79:160-6. doi: 10.1016/j.psyneuen.2017.02.028 37. Kanat M, Heinrichs M, Schwarzwald R, Domes G. Oxytocin attenuates neural reactivity to masked threat cues from the eyes. Neuropsychopharmacology. 2015 Jan;40(2):287-95. doi: 10.1038/npp.2014.183 38. Bertsch K, Gamer M, Schmidt B, Schmidinger I, Walther S, Kästel T, et al. Oxytocin and reduction of social threat hypersensitivity in women with borderline personality disorder. Am J Psychiatry. 2013 Oct;170(10):1169-77. doi: 10.1176/appi.ajp.2013.13020263 39. Insel TR. Translating Oxytocin Neuroscience to the Clinic: A National Institute of Mental Health Perspective. Biol Psychiatry. 2016 Feb 1;79(3):153-4. doi: 10.1016/j.biopsych.2015.02.002 40. Crum KI, Hwang S, Blair KS, Aloi JM, Meffert H, White SF, et al. Interaction of irritability and anxiety on emotional responding and emotion regulation: a functional MRI study. Psychol Med. 2021 Dec;51(16):2778-88. doi: 10.1017/S0033291720001397 41. Mukherjee P, Vilgis V, Rhoads S, Chahal R, Fassbender C, Leibenluft E, et al. Associations of Irritability With Functional Connectivity of Amygdala and Nucleus Accumbens in Adolescents and Young Adults With ADHD. J Atten Disord. 2022 May;26(7):1040-1050. doi: 10.1177/10870547211057074 42. Damen L, Grootjen LN, Juriaans AF, Donze SH, Huisman TM, Visser JA, et al. Oxytocin in young children with Prader-Willi syndrome: Results of a randomized, double-blind, placebo-controlled, crossover trial investigating 3 months of oxytocin. Clin Endocrinol (Oxf). 2021 May;94(5):774-85. doi: 10.1111/cen.14387 43. Miller JL, Tamura R, Butler MG, Kimonis V, Sulsona C, Gold JA, et al. Oxytocin treatment in children with Prader-Willi syndrome: A double-blind, placebo-controlled, crossover study. Am J Med Genet A. 2017 May;173(5):1243-50. doi: 10.1002/ajmg.a.38160 44. Fastman J, Foss-Feig J, Frank Y, Halpern D, Harony-Nicolas H, Layton C, et al. A randomized controlled trial of intranasal oxytocin in Phelan-McDermid syndrome. Mol Autism. 2021 Sep 30;12(1):62. doi: 10.1186/s13229-021-00459-1 45. Kalvin CB, Gladstone TR, Jordan R, Rowley S, Marsh CL, Ibrahim K, et al. Assessing Irritability in Children with Autism Spectrum Disorder Using the Affective Reactivity Index. J Autism Dev Disord. 2021 May;51(5):1496-1507. doi: 10.1007/s10803-020-04627-9 46. Schwartz L, Caixàs A, Dimitropoulos A, Dykens E, Duis J, Einfeld S, Gallagher L, Holland A, Rice L, Roof E, Salehi P, Strong T, Taylor B, Woodcock K. Behavioral features in Prader-Willi syndrome (PWS): consensus paper from the International PWS Clinical Trial Consortium. J Neurodev Disord. 2021 Jun 21;13(1):25. doi: 10.1186/s11689-021-09373-2 47. Kohlenberg TM, Trelles MP, McLarney B, Betancur C, Thurm A, Kolevzon A. Psychiatric illness and regression in individuals with Phelan-McDermid syndrome. J Neurodev Disord. 2020 Feb 12;12(1):7. doi: 10.1186/s11689-020-9309-6 48. Bos PA, Panksepp J, Bluthé RM, van Honk J. Acute effects of steroid hormones and neuropeptides on human social-emotional behavior: a review of single administration studies. Front Neuroendocrinol. 2012 Jan;33(1):17-35. doi: 10.1016/j.yfrne.2011.01.002 49. Parker KJ, Garner JP, Libove RA, Hyde SA, Hornbeak KB, Carson DS, et al. Plasma oxytocin concentrations and OXTR polymorphisms predict social impairments in children with and without autism spectrum disorder. Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):12258-63. doi: 10.1073/pnas.1402236111 50. LoParo D, Waldman ID. The oxytocin receptor gene (OXTR) is associated with autism spectrum disorder: a meta-analysis. Mol Psychiatry. 2015 May;20(5):640-6. doi: 10.1038/mp.2014.77 51. Al-Ali Z, Yasseen AA, Al-Dujailli A, Al-Karaqully AJ, McAllister KA, Jumaah AS. The oxytocin receptor gene polymorphism rs2268491 and serum oxytocin alterations are indicative of autism spectrum disorder: A case-control paediatric study in Iraq with personalized medicine implications. PLoS One. 2022 Mar 22;17(3):e0265217. doi: 10.1371/journal.pone.0265217 52. Mayes SD, Waxmonsky J, Calhoun SL, Kokotovich C, Mathiowetz C, Baweja R. Disruptive mood dysregulation disorder (DMDD) symptoms in children with autism, ADHD, and neurotypical development and impact of co-occurring ODD, depression, and anxiety. Res Autism Spec Disord. 2015 Oct;18:64-72. doi: 10.1016/j.rasd.2015.07.003 53. Mikita N, Hollocks MJ, Papadopoulos AS, Aslani A, Harrison S, Leibenluft E, et al. Irritability in boys with autism spectrum disorders: an investigation of physiological reactivity. J Child Psychol Psychiatry. 2015 Oct;56(10):1118-26. doi: 10.1111/jcpp.12382 54. Bennett JA, Germani T, Haqq AM, Zwaigenbaum L. Autism spectrum disorder in Prader-Willi syndrome: A systematic review. Am J Med Genet A. 2015 Dec;167A(12):2936-44. doi: 10.1002/ajmg.a.37286 55. McCandless SE; Committee on Genetics. Clinical report—health supervision for children with Prader-Willi syndrome. Pediatrics. 2011 Jan;127(1):195-204. doi: 10.1542/peds.2010-2820 56. Rice LJ, Agu J, Carter CS, Harris JC, Nazarloo HP, Naanai H, et al. The relationship between endogenous oxytocin and vasopressin levels and the Prader-Willi syndrome behaviour phenotype. Front Endocrinol. 2023 May 29;14:1183525. doi: 10.3389/fendo.2023.1183525 57. Oztan O, Zyga O, Stafford DEJ, Parker KJ. Linking oxytocin and arginine vasopressin signaling abnormalities to social behavior impairments in Prader-Willi syndrome. Neurosci Biobehav Rev. 2022 Nov;142:104870. doi: 10.1016/j.neubiorev.2022.104870 58. Phelan MC. Deletion 22q13.3 syndrome. Orphanet J Rare Dis. 2008 May 27;3:14. doi: 10.1186/1750-1172-3-14. 59. Moessner R, Marshall CR, Sutcliffe JS, Skaug J, Pinto D, Vincent J, et al. Contribution of SHANK3 mutations to autism spectrum disorder. Am J Hum Genet. 2007 Dec;81(6):1289-97. doi: 10.1086/522590 60. Harony-Nicolas H, Kay M, du Hoffmann J, Klein ME, Bozdagi-Gunal O, Riad M, et al. Oxytocin improves behavioral and electrophysiological deficits in a novel Shank3-deficient rat. Elife. 2017 Jan 31;6:e18904. doi: 10.7554/eLife.18904 61. Ellis EE, Yilanli M, Saadabadi A. Reactive Attachment Disorder. Treasure Island (FL, US): StatPearls Publishing; 2023. 62. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug 28;366:l4898. doi: 10.1136/bmj.l4898 63. Schmidt JD, Huete JM, Fodstad JC, Chin MD, Kurtz PF. An evaluation of the Aberrant Behavior Checklist for children under age 5. Res Dev Disabil. 2013 Apr;34(4):1190-7. doi: 10.1016/j.ridd.2013.01.002 64. Bishop SL, Hus V, Duncan A, Huerta M, Gotham K, Pickles A, et al. Subcategories of restricted and repetitive behaviors in children with autism spectrum disorders. J Autism Dev Disord. 2013 Jun;43(6):1287-97. doi: 10.1007/s10803-012-1671-0 65. Kerr-Gaffney J, Harrison A, Tchanturia K. The social responsiveness scale is an efficient screening tool for autism spectrum disorder traits in adults with anorexia nervosa. Eur Eat Disord Rev. 2020 Jul;28(4):433-44. doi: 10.1002/erv.2736 66. Marzocchi GM, Capron C, Di Pietro M, Duran Tauleria E, Duyme M, Frigerio A, et al. The use of the Strengths and Difficulties Questionnaire (SDQ) in Southern European countries. Eur Child Adolesc Psychiatry. 2004;13 Suppl 2:II40-6. doi: 10.1007/s00787-004-2007-1 67. Stringaris A, Goodman R, Ferdinando S, Razdan V, Muhrer E, Leibenluft E, et al. The Affective Reactivity Index: a concise irritability scale for clinical and research settings. J Child Psychol Psychiatry. 2012 Nov;53(11):1109-17. doi: 10.1111/j.1469-7610.2012.02561.x 68. Saatchi B, Agbayani CG, Clancy SL, Fortier MA. Measuring irritability in young adults: An integrative review of measures and their psychometric properties. J Psychiatr Ment Health Nurs. 2023 Feb;30(1):35-53. doi: 10.1111/jpm.12851 69. Greene RK, Spanos M, Alderman C, Walsh E, Bizzell J, Mosner MG, et al. The effects of intranasal oxytocin on reward circuitry responses in children with autism spectrum disorder. J Neurodev Disord. 2018 Mar 27;10(1):12. doi: 10.1186/s11689-018-9228-y 70. Yatawara CJ, Einfeld SL, Hickie IB, Davenport TA, Guastella AJ. The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial. Mol Psychiatry. 2016 Sep;21(9):1225-31. doi: 10.1038/mp.2015.162 71. Parker KJ, Oztan O, Libove RA, Sumiyoshi RD, Jackson LP, Karhson DS, et al. Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism. Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):8119-24. doi: 10.1073/pnas.1705521114 72. Daniels N, Moerkerke M, Steyaert J, Bamps A, Debbaut E, Prinsen J, et al. Effects of multiple-dose intranasal oxytocin administration on social responsiveness in children with autism: a randomized, placebo-controlled trial. Mol Autism. 2023 Apr 20;14(1):16. doi: 10.1186/s13229-023-00546-5 73. Korisky A, Goldstein A, Gordon I. The dual neural effects of oxytocin in autistic youth: results from a randomized trial. Sci Rep. 2022 Sep 29;12(1):16304. doi: 10.1038/s41598-022-19524-7 74. Guastella AJ, Boulton KA, Whitehouse AJO, Song YJ, Thapa R, Gregory SG, et al. The effect of oxytocin nasal spray on social interaction in young children with autism: a randomized clinical trial. Mol Psychiatry. 2023 Feb;28(2):834-42. doi: 10.1038/s41380-022-01845-8 75. Le J, Zhang L, Zhao W, Zhu S, Lan C, Kou J, et al. Infrequent Intranasal Oxytocin Followed by Positive Social Interaction Improves Symptoms in Autistic Children: A Pilot Randomized Clinical Trial. Psychother Psychosom. 2022;91(5):335-47. doi: 10.1159/000524543 76. Karbasi A, Shafiezadegan Isfahani S, Maracy MR, Sabzghabaee AM. Effect of intranasal oxytocin combination therapy with applied behavior analysis on social impairments in pediatric’s children with autism spectrum disorder. Middle East Curr Psychiatry. 2023;30:35. doi: 10.1186/s43045-023-00300-w 77. Takiguchi S, Makita K, Fujisawa TX, Nishitani S, Tomoda A. Effects of intranasal oxytocin on neural reward processing in children and adolescents with reactive attachment disorder: A randomized controlled trial. Front. Child Adolesc. Psychiatry. 2022;1. doi: 10.3389/frcha.2022.1056115 78. O'Connell LA, Hofmann HA. The vertebrate mesolimbic reward system and social behavior network: a comparative synthesis. J Comp Neurol. 2011 Dec 15;519(18):3599-639. doi: 10.1002/cne.22735 79. Roesch MR, Singh T, Brown PL, Mullins SE, Schoenbaum G. Ventral striatal neurons encode the value of the chosen action in rats deciding between differently delayed or sized rewards. J Neurosci. 2009 Oct 21;29(42):13365-76. doi: 10.1523/JNEUROSCI.2572-09.2009 80. Apps MA, Rushworth MF, Chang SW. The Anterior Cingulate Gyrus and Social Cognition: Tracking the Motivation of Others. Neuron. 2016 May 18;90(4):692-707. doi: 10.1016/j.neuron.2016.04.018 81. Hertrich I, Dietrich S, Blum C, Ackermann H. The Role of the Dorsolateral Prefrontal Cortex for Speech and Language Processing. Front Hum Neurosci. 2021 May 17;15:645209. doi: 10.3389/fnhum.2021.645209 82. Cai RY, Richdale AL, Uljarević M, Dissanayake C, Samson AC. Emotion regulation in autism spectrum disorder: Where we are and where we need to go. Autism Res. 2018 Jul;11(7):962-78. doi: 10.1002/aur.1968 83. Keluskar J, Reicher D, Gorecki A, Mazefsky C, Crowell JA. Understanding, Assessing, and Intervening with Emotion Dysregulation in Autism Spectrum Disorder: A Developmental Perspective. Child Adolesc Psychiatr Clin N Am. 2021 Apr;30(2):335-48. doi: 10.1016/j.chc.2020.10.013 84. Neumann ID, Maloumby R, Beiderbeck DI, Lukas M, Landgraf R. Increased brain and plasma oxytocin after nasal and peripheral administration in rats and mice. Psychoneuroendocrinology. 2013 Oct;38(10):1985-93. doi: 10.1016/j.psyneuen.2013.03.003 85. Bauman MD, Murai T, Hogrefe CE, Platt ML. Opportunities and challenges for intranasal oxytocin treatment studies in nonhuman primates. Am J Primatol. 2018 Oct;80(10):e22913. doi: 10.1002/ajp.22913 86. Freeman SM, Samineni S, Allen PC, Stockinger D, Bales KL, Hwa GG, et al. Plasma and CSF oxytocin levels after intranasal and intravenous oxytocin in awake macaques. Psychoneuroendocrinology. 2016 Apr;66:185-94. doi: 10.1016/j.psyneuen.2016.01.014 87. Lee MR, Shnitko TA, Blue SW, Kaucher AV, Winchell AJ, Erikson DW, et al. Labeled oxytocin administered via the intranasal route reaches the brain in rhesus macaques. Nat Commun. 2020 Jun 3;11(1):2783. doi: 10.1038/s41467-020-15942-1 88. Striepens N, Kendrick KM, Hanking V, Landgraf R, Wüllner U, Maier W, et al. Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans. Sci Rep. 2013 Dec 6;3:3440. doi: 10.1038/srep03440 89. Quintana DS, Lischke A, Grace S, Scheele D, Ma Y, Becker B. Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research. Mol Psychiatry. 2021 Jan;26(1):80-91. doi: 10.1038/s41380-020-00864-7 90. Mens WB, Witter A, van Wimersma Greidanus TB. Penetration of neurohypophyseal hormones from plasma into cerebrospinal fluid (CSF): half-times of disappearance of these neuropeptides from CSF. Brain Res. 1983 Feb 28;262(1):143-9. doi: 10.1016/0006-8993(83)90478-x 91. Quintana DS, Westlye LT, Rustan ØG, Tesli N, Poppy CL, Smevik H, et al. Low-dose oxytocin delivered intranasally with Breath Powered device affects social-cognitive behavior: a randomized four-way crossover trial with nasal cavity dimension assessment. Transl Psychiatry. 2015 Jul 14;5(7):e602. doi: 10.1038/tp.2015.93 92. Quintana DS, Westlye LT, Alnæs D, Rustan ØG, Kaufmann T, Smerud KT, et al. Low dose intranasal oxytocin delivered with Breath Powered device dampens amygdala response to emotional stimuli: A peripheral effect-controlled within-subjects randomized dose-response fMRI trial. Psychoneuroendocrinology. 2016 Jul;69:180-8. doi: 10.1016/j.psyneuen.2016.04.010 93. Quintana DS, Westlye LT, Alnæs D, Kaufmann T, Mahmoud RA, Smerud KT, et al. Low-dose intranasal oxytocin delivered with Breath Powered device modulates pupil diameter and amygdala activity: a randomized controlled pupillometry and fMRI study. Neuropsychopharmacology. 2019 Jan;44(2):306-13. doi: 10.1038/s41386-018-0241-3 94. Gouveia FV, Hamani C, Fonoff ET, Brentani H, Alho EJL, de Morais RMCB, et al. Amygdala and Hypothalamus: Historical Overview With Focus on Aggression. Neurosurgery. 2019 Jul 1;85(1):11-30. doi: 10.1093/neuros/nyy635 95. Berends YR, Tulen JHM, Wierdsma AI, van Pelt J, Kushner SA, van Marle HJC. Oxytocin, vasopressin and trust: Associations with aggressive behavior in healthy young males. Physiol Behav. 2019 May 15;204:180-5. doi: 10.1016/j.physbeh.2019.02.027 96. Berends YR, Tulen JHM, Wierdsma AI, van Pelt J, Feldman R, Zagoory-Sharon O, et al. Intranasal administration of oxytocin decreases task-related aggressive responses in healthy young males. Psychoneuroendocrinology. 2019 Aug;106:147-54. doi: 10.1016/j.psyneuen.2019.03.027 97. Alcorn JL III, Green CE, Schmitz J, Lane SD. Effects of oxytocin on aggressive responding in healthy adult men. Behav Pharmacol. 2015 Dec;26(8 Spec No):798-804. doi: 10.1097/FBP.0000000000000173 98. Ne'eman R, Perach-Barzilay N, Fischer-Shofty M, Atias A, Shamay-Tsoory SG. Intranasal administration of oxytocin increases human aggressive behavior. Horm Behav. 2016 Apr;80:125-31. doi: 10.1016/j.yhbeh.2016.01.015 99. Koch SB, van Zuiden M, Nawijn L, Frijling JL, Veltman DJ, Olff M. Intranasal Oxytocin Administration Dampens Amygdala Reactivity towards Emotional Faces in Male and Female PTSD Patients. Neuropsychopharmacology. 2016 May;41(6):1495-504. doi: 10.1038/npp.2015.299 100. Labuschagne I, Phan KL, Wood A, Angstadt M, Chua P, Heinrichs M, et al. Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. Neuropsychopharmacology. 2010 Nov;35(12):2403-13. doi: 10.1038/npp.2010.123 101. Lischke A, Herpertz SC, Berger C, Domes G, Gamer M. Divergent effects of oxytocin on (para-)limbic reactivity to emotional and neutral scenes in females with and without borderline personality disorder. Soc Cogn Affect Neurosci. 2017 Nov 1;12(11):1783-92. doi: 10.1093/scan/nsx107 102. Spengler FB, Schultz J, Scheele D, Essel M, Maier W, Heinrichs M, et al. Kinetics and Dose Dependency of Intranasal Oxytocin Effects on Amygdala Reactivity. Biol Psychiatry. 2017 Dec 15;82(12):885-94. doi: 10.1016/j.biopsych.2017.04.015

引用本文

Kennet Sorenson,Emilee Kendall,Hannah Grell,Minjoo Kang,Christopher Shaffer,Soonjo Hwang*. Intranasal Oxytocin in Pediatric Populations: Exploring the Potential for Reducing Irritability and Modulating Neural Responses: A Mini Review, Journal of Psychiatry and Brain Science. 2023; 8; (4). https://doi.org/10.20900/jpbs.20230008.

文献评论

相关学者

相关机构